share_log

騰盛博藥-B:截至2024年2月29日之股份發行人的證券變動月報表

BRII-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

香港交易所 ·  Mar 5 03:25
Summary by Moomoo AI
腾盛博药生物科技有限公司於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年2月29日的公司股份變動情況。報告顯示,公司的法定/註冊股本維持在1,200,000,000股,每股面值0.000005美元,總股本為6,000美元,本月無增減變動。此外,公司根據不同的股份激勵計劃及購股權計劃,詳述了股份期權的行使情況,包括行使價格、期權數目的變動以及因行使期權而可能發行的新股份數目。報告中提到,於2024年2月,共有87,625份受限制股份單位已失效。本月內因行使期權所得資金總額為3,909.13港元。公司確認所有證券發行均已獲董事會授權,並符合香港聯合交易所有限公司證券上市規則的相關要求。
腾盛博药生物科技有限公司於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年2月29日的公司股份變動情況。報告顯示,公司的法定/註冊股本維持在1,200,000,000股,每股面值0.000005美元,總股本為6,000美元,本月無增減變動。此外,公司根據不同的股份激勵計劃及購股權計劃,詳述了股份期權的行使情況,包括行使價格、期權數目的變動以及因行使期權而可能發行的新股份數目。報告中提到,於2024年2月,共有87,625份受限制股份單位已失效。本月內因行使期權所得資金總額為3,909.13港元。公司確認所有證券發行均已獲董事會授權,並符合香港聯合交易所有限公司證券上市規則的相關要求。
Teng Sheng Bo Pharmaceutical Biotechnology Co., Ltd. filed its latest Securities Change Month Report with Hong Kong Trading and Settlement Limited on March 5, 2024, reporting the changes in the company's shares for the year ended February 29, 2024. The report showed that the company's regulated/registered share capital remained at 1,200,000,000 shares with a face value of $0.00005 per share and a total share capital of $6,000, unchanged this month. In addition, the Company details the exercise of share options under different share incentive schemes and share option plans, including the exercise price, the change in the number of options and the number of new shares that may be issued as a result of the exercise of options. The report noted that as of...Show More
Teng Sheng Bo Pharmaceutical Biotechnology Co., Ltd. filed its latest Securities Change Month Report with Hong Kong Trading and Settlement Limited on March 5, 2024, reporting the changes in the company's shares for the year ended February 29, 2024. The report showed that the company's regulated/registered share capital remained at 1,200,000,000 shares with a face value of $0.00005 per share and a total share capital of $6,000, unchanged this month. In addition, the Company details the exercise of share options under different share incentive schemes and share option plans, including the exercise price, the change in the number of options and the number of new shares that may be issued as a result of the exercise of options. The report noted that as of February 2024, a total of 87,625 units of restricted stock had lapsed. The total amount of capital gained from the exercise of options during the month was HK$3,909.13. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more